n | T0 | T12 | Δ (95% CI) | SRM (95% CI) | ES (95% CI) | |
---|---|---|---|---|---|---|
MHQ | ||||||
Benefit | 276 | 51.15 | 57.83 | 6.68 (3.75 to 9.61) | 0.26 (-1.74 to 2.27) | 1.03 (-0.97 to 3.04) |
No benefit | 110 | 50.86 | 49.15 | -1.71 (-6.21 to 2.79) | -0.07 (-3.18 to 3.05) | 1.02 (-2.09 to 4.14 |
Harm | 6 | 46.33 | 46.34 | 0.01 (-20.65 to 20.67) | 0.00 (-11.13 to 11.13) | 1.22 (-9.91 to 12.35) |
EQ-5D (utility) | ||||||
Benefit | 276 | 0.59 | 0.61 | 0.06 (0.02 to 0.10) | 0.17 (0.14 to 0.19) | 0.24 (0.20to 0.26) |
No benefit | 110 | 0.59 | 0.57 | -0.03 (-0.09 to 0.03) | -0.09 (-0.14 to -0.05) | -0.13 (-0.17 to -0.08) |
Harm | 6 | 0.53 | 0.54 | -0.05 (-0.03 to 0.23) | -0.15 (-0.25 to -0.03) | -0.22 (-0.34 to -0.09) |
EQ-5D (VAS) | ||||||
Benefit | 276 | 69.57 | 67.92 | -1.65 (-3.67 to 0.37) | -0.06 (-2.08 to 1.96) | -0.08 (-2.10 to 1.94) |
No benefit | 110 | 64.89 | 61.3 | -3.59 (- 7.08 to -0.09) | -0.13 (-3.63 to 3.35) | -0.19 (-3.68 to 3.30) |
Harm | 6 | 60.16 | 57 | -3.16 (-19.83 to 13.56) | -0.11 (-16.83 to 16.61) | -0.15 (-16.87 to 18.42) |
SF-12 (PCS) | ||||||
Benefit | 276 | 34.44 | 32.93 | -1.51 (-2.77 to -0.24) | -0.08 (-1.35 to 1.18) | -0.12 (-1.38 to 1.15) |
No benefit | 110 | 31.79 | 31 | -0.79 (-2.86 to 1.28) | -0.15 (-2.13 to 2.02) | -0.08 (-2.15 to 1.99) |
Harm | 6 | 24.84 | 36.08 | 11.24 (-0.27 to 22.75) | 0.67 (-10.84 to 12.19) | 0.99 (-10.52 to 12.51) |
SF-12 (MCS) | ||||||
Benefit | 276 | 48.26 | 47.31 | -0.95 (-2.44 to 0.54) | -0.05 (-1.54 to 1.45) | -0.06 (-1.56 to 1.42) |
No benefit | 110 | 48.04 | 49.44 | 1.4 (-1.06 to 3.86) | 0.08 (-2.38 to 2.54) | 0.12 (-2.34 to 2.57) |
Harm | 6 | 32.7 | 37.74 | 5.04 (-11.59 to 21.67) | 0.21 (-16.42 to 16.84) | 0.31 (-16.32 to 16.95) |
SF-6D | ||||||
Benefit | 276 | 0.64 | 0.63 | -0.01 (-0.03 to 0.01) | -0.04 (-0.06 to -0.02) | -0.06 (-0.07 to -0.04) |
No benefit | 110 | 0.63 | 0.63 | 0 (-0.02 to 0.02) | 0 (-0.02 to 0.02) | 0 (-0.02 to 0.02) |
Harm | 6 | 0.58 | 0.58 | 0 (-0.06 to 0.06) | 0 (-0.06 to 0.06) | 0 (-0.06 to 0.06) |